Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA OKs expansion of DMD stem cell trial, allows 30 more boys

18 August 2026 · By · Wire by Fusion42

Published

18 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at musculardystrophynews.com →

◆ Verified

Fusion42 · 18 August 2026 · Fusion42 review

The FDA has authorised the expansion of a stem cell trial targeting Duchenne muscular dystrophy (DMD), allowing for enrolment of 30 additional boys to further test the therapy's safety and effectiveness.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

FDA approval to expand this DMD trial opens a wider patient population for your stem cell therapy testing. You can now accelerate recruitment and data gathering to build clinical validation and investor confidence.

◆ Coverage

1 source · 18 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalstem-cellduchenne-muscular-dystrophyclinical-trialbiotech